These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1079 related articles for article (PubMed ID: 22208782)

  • 21. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
    Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
    J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
    Lau LF; Williams DS; Lee ST; Scott AM; Christophi C; Muralidharan V
    Ann Surg Oncol; 2014 Jul; 21(7):2420-8. PubMed ID: 24595797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
    Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
    Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY; Kim SK; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Park IH; Lee KS; Shin KH; Lee S; Kim SW; Kang HS; Ro J
    Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
    Kim MK; Cho KJ; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Song HJ; Ryu JS; Kim SB
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):115-21. PubMed ID: 19251379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
    Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
    Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
    Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone.
    Shenfine J; Barbour AP; Wong D; Thomas J; Martin I; Gotley DC; Smithers BM
    Dis Esophagus; 2009; 22(8):668-75. PubMed ID: 19222534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
    Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
    Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.